| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Haya Ascher-Svanum, Michael D Stensland, Xiaomei Peng, Douglas E Faries, Virginia L Stauffer, Olawale O Osuntokun, John M Kan. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current medical research and opinion. vol 27. issue 1. 2011-04-01. PMID:21110749. |
information about the cost-effectiveness of aripiprazole relative to other atypical antipsychotics in the treatment of patients with schizophrenia is limited. |
2011-04-01 |
2023-08-12 |
Not clear |
| Haya Ascher-Svanum, Michael D Stensland, Xiaomei Peng, Douglas E Faries, Virginia L Stauffer, Olawale O Osuntokun, John M Kan. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current medical research and opinion. vol 27. issue 1. 2011-04-01. PMID:21110749. |
the objective of this study was to compare the cost-effectiveness of olanzapine to aripiprazole in the treatment of schizophrenia from the perspective of public payers in the united states. |
2011-04-01 |
2023-08-12 |
Not clear |
| Gilles Gavaudan, David Magalon, Julien Cohen, Christophe Lançon, Georges Léonetti, Anne-Laure Pélissier-Alico. Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. Journal of forensic sciences. vol 55. issue 6. 2011-03-29. PMID:20579229. |
based on recent advances in research on pg and adverse drug reactions to dopamine agonists in parkinson's disease, we postulate a link between aripiprazole and pg in both our patients with schizophrenia and raise the question of criminal responsibility. |
2011-03-29 |
2023-08-12 |
Not clear |
| Vicki P Hoffmann, Michael Case, Virginia L Stauffer, Jennie G Jacobson, Robert R Conle. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. Journal of clinical psychopharmacology. vol 30. issue 6. 2011-02-22. PMID:21105275. |
predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. |
2011-02-22 |
2023-08-12 |
human |
| Vicki P Hoffmann, Michael Case, Virginia L Stauffer, Jennie G Jacobson, Robert R Conle. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. Journal of clinical psychopharmacology. vol 30. issue 6. 2011-02-22. PMID:21105275. |
data were from three 24- to 28-week randomized, controlled studies comparing olanzapine to ziprasidone or aripiprazole for treatment of schizophrenia. |
2011-02-22 |
2023-08-12 |
human |
| Marianne Ulcickas Yood, Gerald Delorenze, Charles P Quesenberry, Ai-Lin Tsai, Syd Phillips, Vincent J Willey, Steve J Niemcryk, Karen Wells, Mary Lou Skovron, Mark J Cziraky, William Carson, Susan A Oliveri. Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiology and drug safety. vol 19. issue 11. 2011-02-07. PMID:20925132. |
to fulfill a postmarketing request, our objective was to determine suicide event (attempted or completed) incidence in patients with schizophrenia or bipolar disorder, prescribed aripiprazole. |
2011-02-07 |
2023-08-12 |
Not clear |
| Makoto Ishitobi, Hirotaka Kosaka, Ken-ichi Shukunami, Tetsuhito Murata, Yuji Wad. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 7. 2010-12-29. PMID:20647025. |
adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia. |
2010-12-29 |
2023-08-12 |
Not clear |
| Jeffrey Rado, Philip G Janica. Aripiprazole for late-life schizophrenia. Clinical interventions in aging. vol 5. 2010-11-30. PMID:20852672. |
aripiprazole for late-life schizophrenia. |
2010-11-30 |
2023-08-12 |
Not clear |
| Jeffrey Rado, Philip G Janica. Aripiprazole for late-life schizophrenia. Clinical interventions in aging. vol 5. 2010-11-30. PMID:20852672. |
with this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole. |
2010-11-30 |
2023-08-12 |
Not clear |
| Eiji Kirin. Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clinical schizophrenia & related psychoses. vol 4. issue 3. 2010-11-30. PMID:20880829. |
prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. |
2010-11-30 |
2023-08-12 |
Not clear |
| Eiji Kirin. Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: a case report. Clinical schizophrenia & related psychoses. vol 4. issue 3. 2010-11-30. PMID:20880829. |
we present the case of a fifteen-year-old adolescent male with schizophrenia who had long-term catatonic stupor and was successfully treated with aripiprazole. |
2010-11-30 |
2023-08-12 |
Not clear |
| Takaaki Matsuo, Yasuhiko Izumi, Toshiaki Kume, Yuki Takada-Takatori, Hideyuki Sawada, Akinori Akaik. Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures. Neuroscience letters. vol 481. issue 2. 2010-11-22. PMID:20600606. |
aripiprazole, a dopamine d(2) receptor partial agonist, is used to treat schizophrenia. |
2010-11-22 |
2023-08-12 |
rat |
| Pei-Lin Hwang, Shao-Yun Wei, Hsin-Hua Yeh, Ju-Yun Ko, Cheng-Chen Chang, Su-Hwei Che. Simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia. Electrophoresis. vol 31. issue 16. 2010-11-16. PMID:20665528. |
simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia. |
2010-11-16 |
2023-08-12 |
human |
| Takashi Futamura, Satoshi Akiyama, Haruhiko Sugino, Andy Forbes, Robert D McQuade, Tetsuro Kikuch. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 6. 2010-11-02. PMID:20561555. |
these results of aripiprazole suggest that the attenuation effect of aripiprazole was mediated by 5-ht1a receptors and imply that aripiprazole may have therapeutic value in treating drug-induced psychosis and schizophrenia. |
2010-11-02 |
2023-08-12 |
mouse |
| Jimmi Nielsen, Søren Skadhede, Christoph U Correl. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 9. 2010-10-28. PMID:20520598. |
in addition to general diabetes risk factors, such as age, hypertension, and dyslipidemia, diabetes is promoted in schizophrenia patients by initial and current treatment with olanzapine and mid-potency fgas, as well as by current treatment with or low-potency first-generation antipsychotics and clozapine, whereas current aripiprazole treatment reduced diabetes risk. |
2010-10-28 |
2023-08-12 |
Not clear |
| J P Docherty, R A Baker, J Eudicone, S Mathew, R N Marcus, R D McQuade, R Mankosk. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophrenia research. vol 120. issue 1-3. 2010-10-20. PMID:20547037. |
effect of aripiprazole versus haloperidol on panss prosocial items in early-episode patients with schizophrenia. |
2010-10-20 |
2023-08-12 |
Not clear |
| J P Docherty, R A Baker, J Eudicone, S Mathew, R N Marcus, R D McQuade, R Mankosk. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophrenia research. vol 120. issue 1-3. 2010-10-20. PMID:20547037. |
this post-hoc, pooled analysis of two studies compared the effect of aripiprazole versus haloperidol on social functioning in early-episode schizophrenia. |
2010-10-20 |
2023-08-12 |
Not clear |
| John M Kane, Thomas R E Barnes, Christoph U Correll, Gary Sachs, Peter Buckley, James Eudicone, Robert McQuade, Quynh-Van Tran, Andrei Pikalov, Sheila Assunção-Talbot. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. Journal of psychopharmacology (Oxford, England). vol 24. issue 7. 2010-09-16. PMID:20008446. |
discontinuation due to akathisia was low in both the schizophrenia trials (aripiprazole 0.3%; placebo 0%; aripiprazole 0.9%; haloperidol 2.3%; aripiprazole 1.2%; olanzapine 0.2%) and the bipolar trials (aripiprazole 2.3%; placebo 0%). |
2010-09-16 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Kyung-Yeol Bae, Su-Jin Yang, Jin-Sang Yoo. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clinical neuropharmacology. vol 33. issue 3. 2010-08-31. PMID:20502130. |
effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. |
2010-08-31 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Kyung-Yeol Bae, Su-Jin Yang, Jin-Sang Yoo. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clinical neuropharmacology. vol 33. issue 3. 2010-08-31. PMID:20502130. |
this study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to aripiprazole for the treatment of schizophrenia. |
2010-08-31 |
2023-08-12 |
Not clear |